Jason Butler
Stock Analyst at JMP Securities
(3.94)
# 1,063
Out of 4,479 analysts
100
Total ratings
50%
Success rate
9.27%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATHA Athira Pharma | Reiterates: Market Outperform | $19 | $2.52 | +653.97% | 5 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Market Outperform | $14 | $1.49 | +839.60% | 6 | Jun 4, 2024 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $54.84 | +42.23% | 11 | May 31, 2024 | |
| ARGX argenx SE | Maintains: Market Outperform | $471 → $468 | $435.49 | +7.47% | 5 | May 10, 2024 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $85 → $83 | $20.39 | +307.06% | 7 | May 9, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $72 → $71 | $51.30 | +38.40% | 8 | May 8, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Market Outperform | $23 | $4.01 | +474.28% | 3 | Apr 19, 2024 | |
| RZLT Rezolute | Reiterates: Market Outperform | $7 | $4.21 | +66.27% | 6 | Apr 19, 2024 | |
| CRMD CorMedix | Reiterates: Market Outperform | $19 | $4.12 | +361.17% | 6 | Apr 9, 2024 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $8 → $10 | $2.42 | +313.22% | 3 | Mar 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $44 → $39 | $15.84 | +146.21% | 11 | Mar 12, 2024 | |
| GHRS GH Research | Maintains: Market Outperform | $50 → $39 | $11.91 | +227.46% | 3 | Mar 1, 2024 | |
| MOR MorphoSys AG | Reiterates: Market Outperform | $17 | $18.10 | -6.08% | 3 | Nov 21, 2023 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $12.16 | +212.50% | 6 | Nov 14, 2023 | |
| IRWD Ironwood Pharmaceuticals | Initiates: Market Outperform | $22 | $6.22 | +253.70% | 1 | Sep 28, 2023 | |
| TRVN Trevena | Reiterates: Market Outperform | $2 | $0.21 | +874.18% | 2 | May 17, 2023 | |
| SYRS Syros Pharmaceuticals | Maintains: Market Outperform | $16 → $15 | $5.00 | +200.00% | 2 | May 11, 2023 | |
| NERV Minerva Neurosciences | Downgrades: Market Perform | n/a | $3.08 | - | 1 | Oct 17, 2022 | |
| MRNS Marinus Pharmaceuticals | Maintains: Market Outperform | $21 → $22 | $1.19 | +1,748.74% | 1 | Mar 22, 2022 | |
| QNRX Quoin Pharmaceuticals | Initiates: Market Outperform | n/a | $0.58 | - | 1 | Dec 15, 2021 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | n/a | $13.45 | - | 4 | Nov 23, 2021 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | n/a | $0.58 | - | 1 | Nov 10, 2021 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | n/a | $3.13 | - | 1 | Nov 8, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Outperform | n/a | $2.34 | - | 1 | May 5, 2021 | |
| OVID Ovid Therapeutics | Downgrades: Market Perform | n/a | $0.77 | - | 1 | Dec 2, 2020 | |
| ITCI Intra-Cellular Therapies | Upgrades: Market Outperform | n/a | $68.54 | - | 1 | Aug 24, 2017 |
Athira Pharma
Jun 20, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $2.52
Upside: +653.97%
Precigen
Jun 4, 2024
Reiterates: Market Outperform
Price Target: $14
Current: $1.49
Upside: +839.60%
Cytokinetics
May 31, 2024
Reiterates: Market Outperform
Price Target: $78
Current: $54.84
Upside: +42.23%
argenx SE
May 10, 2024
Maintains: Market Outperform
Price Target: $471 → $468
Current: $435.49
Upside: +7.47%
Prothena Corporation
May 9, 2024
Maintains: Market Outperform
Price Target: $85 → $83
Current: $20.39
Upside: +307.06%
Halozyme Therapeutics
May 8, 2024
Maintains: Market Outperform
Price Target: $72 → $71
Current: $51.30
Upside: +38.40%
Vigil Neuroscience
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $23
Current: $4.01
Upside: +474.28%
Rezolute
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $4.21
Upside: +66.27%
CorMedix
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $4.12
Upside: +361.17%
Aquestive Therapeutics
Mar 15, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $2.42
Upside: +313.22%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $15.84
Upside: +146.21%
GH Research
Mar 1, 2024
Maintains: Market Outperform
Price Target: $50 → $39
Current: $11.91
Upside: +227.46%
MorphoSys AG
Nov 21, 2023
Reiterates: Market Outperform
Price Target: $17
Current: $18.10
Upside: -6.08%
Viridian Therapeutics
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $12.16
Upside: +212.50%
Ironwood Pharmaceuticals
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $6.22
Upside: +253.70%
Trevena
May 17, 2023
Reiterates: Market Outperform
Price Target: $2
Current: $0.21
Upside: +874.18%
Syros Pharmaceuticals
May 11, 2023
Maintains: Market Outperform
Price Target: $16 → $15
Current: $5.00
Upside: +200.00%
Minerva Neurosciences
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.08
Upside: -
Marinus Pharmaceuticals
Mar 22, 2022
Maintains: Market Outperform
Price Target: $21 → $22
Current: $1.19
Upside: +1,748.74%
Quoin Pharmaceuticals
Dec 15, 2021
Initiates: Market Outperform
Price Target: n/a
Current: $0.58
Upside: -
Enanta Pharmaceuticals
Nov 23, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $13.45
Upside: -
HOOKIPA Pharma
Nov 10, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $0.58
Upside: -
Arbutus Biopharma
Nov 8, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $3.13
Upside: -
Esperion Therapeutics
May 5, 2021
Maintains: Market Outperform
Price Target: n/a
Current: $2.34
Upside: -
Ovid Therapeutics
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.77
Upside: -
Intra-Cellular Therapies
Aug 24, 2017
Upgrades: Market Outperform
Price Target: n/a
Current: $68.54
Upside: -